CN110917132A - Vaginal squamous epithelium repair aqua and preparation method thereof - Google Patents
Vaginal squamous epithelium repair aqua and preparation method thereof Download PDFInfo
- Publication number
- CN110917132A CN110917132A CN201911314731.2A CN201911314731A CN110917132A CN 110917132 A CN110917132 A CN 110917132A CN 201911314731 A CN201911314731 A CN 201911314731A CN 110917132 A CN110917132 A CN 110917132A
- Authority
- CN
- China
- Prior art keywords
- vaginal
- squamous epithelium
- estrogen
- aqua
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000981 epithelium Anatomy 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 230000008439 repair process Effects 0.000 title abstract description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 29
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 24
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 12
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 12
- 239000011718 vitamin C Substances 0.000 claims abstract description 12
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 102000008186 Collagen Human genes 0.000 claims abstract description 11
- 108010035532 Collagen Proteins 0.000 claims abstract description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 11
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 11
- 102000004338 Transferrin Human genes 0.000 claims abstract description 11
- 108090000901 Transferrin Proteins 0.000 claims abstract description 11
- 229920001436 collagen Polymers 0.000 claims abstract description 11
- 239000004310 lactic acid Substances 0.000 claims abstract description 11
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 11
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 11
- 239000001540 sodium lactate Substances 0.000 claims abstract description 11
- 229940005581 sodium lactate Drugs 0.000 claims abstract description 11
- 235000011088 sodium lactate Nutrition 0.000 claims abstract description 11
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 11
- 239000012581 transferrin Substances 0.000 claims abstract description 11
- 239000008213 purified water Substances 0.000 claims abstract description 10
- 230000010261 cell growth Effects 0.000 claims abstract description 6
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 4
- 210000001339 epidermal cell Anatomy 0.000 claims abstract 2
- 239000003102 growth factor Substances 0.000 claims abstract 2
- 210000001215 vagina Anatomy 0.000 claims description 14
- 239000007921 spray Substances 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 10
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 9
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 7
- 229940116977 epidermal growth factor Drugs 0.000 claims description 7
- 229930182816 L-glutamine Natural products 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 229960005188 collagen Drugs 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229960000448 lactic acid Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 2
- 229940011871 estrogen Drugs 0.000 abstract description 22
- 239000000262 estrogen Substances 0.000 abstract description 22
- 206010047791 Vulvovaginal dryness Diseases 0.000 abstract description 15
- 208000004746 Atrophic Vaginitis Diseases 0.000 abstract description 14
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 abstract description 14
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 abstract description 14
- 210000004877 mucosa Anatomy 0.000 abstract description 3
- 208000009849 Female Genital Neoplasms Diseases 0.000 abstract description 2
- 230000004888 barrier function Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 206010003694 Atrophy Diseases 0.000 description 9
- 230000037444 atrophy Effects 0.000 description 9
- 230000036541 health Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 102400001368 Epidermal growth factor Human genes 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 208000004483 Dyspareunia Diseases 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000005081 epithelial layer Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a vaginal squamous epithelium repair water aqua and a preparation method thereof, which solve the problem that the risk of causing gynecological tumor exists because the vaginal dryness and atrophic vaginitis are mainly treated by estrogen at present, and the invention comprises the following components in percentage by mass: l-glutamine: 0.005% -1%; 0.001% -0.5% of epidermal cell growth factor; transferrin: 0.001% -0.5%; 0.005% -1% of vitamin C; hydrolyzing collagen: 0.1% -10%; sodium hyaluronate: 0.1% -1.0%; glycerol: 5% -10%; lactic acid: 0.1% -1.0%; sodium lactate: 0.2% -2.0%; the balance being purified water. The technical scheme can repair the vaginal squamous epithelium layer and recover the barrier function of the vaginal mucosa, does not depend on estrogen, and does not have the risk factor of the estrogen.
Description
Technical Field
The invention relates to the field of biological medicines, and particularly relates to a vaginal squamous epithelium repair aqua and a preparation method thereof.
Background
Vaginal dryness and atrophic vaginitis are caused by atrophy, incompleteness or disappearance of the squamous epithelial layer of the vagina after a decrease in estrogen levels. The vaginal mucosa consists of non-keratinized stratified squamous epithelium rich in glycogen and basement membrane rich in fiber. The stratified squamous epithelium is rich in glycogen and moist and elastic in vaginal mucosa when the female is in the second and third years of age. As the estrogen is reduced, the epithelium is atrophied, the squamous cell layer disappears, only basal layer cells and accessory basal layer cells which are poor in nutrition and easy to fall villi are reserved, and in the case, the discomfort such as dryness or stabbing pain can be caused, and the infection is easily caused by the formation of small lacerations; secondly, the vaginal suppository is easy to be infected by bacteria and permeated by toxic metabolites to generate atrophic vaginitis. At present, estrogen medicines are commonly used in clinic to relieve symptoms, but the use of estrogen is double-edged sword, so that the risk of gynecological tumor is caused, and the use of estrogen for people with uterine fibroids and breast cancer history is strictly limited.
Disclosure of Invention
The invention aims to solve the defects and provides the vaginal squamous epithelium repairing aqua and the preparation method thereof.
The above object of the present invention is achieved by the following technical means: the vaginal squamous epithelium repairing water aqua is characterized by comprising the following components in percentage by mass:
l-glutamine: 0.005% -1%;
0.001% -0.5% of Epidermal Growth Factor (EGF);
transferrin: 0.001% -0.5%;
0.005% -1% of vitamin C;
hydrolyzing collagen: 0.1% -10%;
sodium hyaluronate: 0.1% -1.0%;
glycerol: 5% -10%;
lactic acid: 0.1% -1.0%;
sodium lactate: 0.2% -2.0%;
the balance being purified water.
Since the shrinking and weakening of the squamous epithelial layer and the disappearance of damage are the speed of the proliferation and the regeneration of the squamous epithelial cells cannot catch up with the speed of apoptosis, the efficacy of the product formula mainly aims at promoting the growth and the proliferation of cells and controlling the speed of apoptosis.
The L-glutamine is a main energy source and a nitrogen source for cell growth, is essential amino acid for synthesizing purine, pyrimidine, protein and polypeptide in cells, and is added to ensure a nutrient source for epithelial cell growth so as to avoid poor cell growth. The EGF can accelerate the transition of cells from interphase to interphase, shorten the multiplication time of cell proliferation and promote the cell proliferation and division. Transferrin and small molecule hydrolyzed collagen provide energy and nutrition for cell growth and proliferation. Free radicals generated in the process of cell physiological metabolism are gathered on cell membranes to promote cell membrane fusion to cause apoptosis, vitamin C has strong effects of resisting oxidation and removing free radicals, and the apoptosis speed is controlled after the vitamin C is added. The sodium hyaluronate and the glycerin have good moisturizing effect, and can quickly replenish water to relieve uncomfortable symptoms such as dryness and the like after being used. Lactic acid and sodium lactate are buffer systems, so that the pH value of the product is in a stable weak acid state, and the product is suitable for the vaginal environment.
Preferably, the components and the formula thereof are as follows by mass percent:
l-glutamine 0.01%;
epidermal growth factor 0.02%;
transferrin is 0.02%;
vitamin C is 0.05%;
the hydrolyzed collagen is 2%;
0.2% of sodium hyaluronate;
5% of glycerin;
0.5 percent of lactic acid;
sodium lactate is 1 percent;
the purified water was 91.2%.
A preparation method of a vaginal squamous epithelium repairing water aqua comprises the steps of dissolving hydrolyzed collagen, sodium hyaluronate, glycerol, lactic acid and sodium lactate in purified water, heating to 80 ℃, keeping the temperature at 80 ℃ for 20 minutes, then cooling, adding L-glutamine, epidermal growth factor, transferrin and vitamin C when the temperature of the system is reduced to be within 40 ℃, and stirring uniformly to obtain the vaginal squamous epithelium repairing water aqua.
Furthermore, the prepared aqueous solution is subpackaged in a trunk tube spray bottle, the front half section of the trunk tube wall of the spray bottle is provided with a plurality of uniformly arranged small holes, and when the spray bottle is used, the trunk tube of the spray bottle is deeply inserted into a vagina and is pressed to spray liquid to the vaginal wall.
A vagina squamous epithelium repair aqua and a preparation method thereof, the product formula emphasizes various nutrients and energy substances required by the growth and proliferation of epithelial cells, functional components for promoting the division of the epithelial cells and removing free radicals to reduce apoptosis are added, simultaneously, the uncomfortable symptoms of vagina dryness and atrophic vaginitis can be rapidly relieved, and the formula system is also suitable for the vaginal tissue environment; the preparation method greatly retains the biological activity of each component, and the compounding performance of each component is good.
Detailed Description
The present invention will be described in more detail with reference to examples.
Example 1
A vaginal squamous epithelium repairing aqua is prepared by dissolving hydrolyzed collagen, sodium hyaluronate, glycerol, lactic acid and sodium lactate in purified water, heating to 80 deg.C, holding at 80 deg.C for 20 min, cooling, adding L-glutamine, EGF, transferrin and vitamin C when the temperature of the system is reduced to below 40 deg.C, stirring, and packaging in a nasal tube spray bottle with uniformly arranged pores at the front half section of nasal tube wall. When in use, the trunk catheter is rotated by 90 degrees to penetrate into the vagina, and the liquid is sprayed to the wall of the vagina by pressing.
The prepared components have the following mass percentages:
l-glutamine: 0.005% -1%;
0.001% -0.5% of Epidermal Growth Factor (EGF);
transferrin: 0.001% -0.5%;
0.005% -1% of vitamin C;
hydrolyzing collagen: 0.1% -10%;
sodium hyaluronate: 0.1% -1.0%;
glycerol: 5% -10%;
lactic acid: 0.1% -1.0%;
sodium lactate: 0.2% -2.0%;
the balance being purified water.
The selection of the components and the selection of the weight ratio in the technical scheme can be freely proportioned according to the range described in the claims, and the selection is not exemplified here.
In order to verify the therapeutic effect of the product, one of the formulations was used for a control test.
The water aqua used in the test comprises the following components in parts by weight:
0.01 percent of L-glutamine;
EGF 0.02％；
0.02% of transferrin;
0.05% of vitamin C;
hydrolyzed collagen 2%
0.2 percent of sodium hyaluronate
5 percent of glycerin
0.5 percent of lactic acid;
sodium lactate 1 percent;
purified water 91.2%.
Evaluation of action of vaginal squamous epithelium repair water agent on vaginal dryness and atrophic vaginitis
In order to verify the effect of the invention, 60 cases of patients with vaginal dryness and atrophic vaginitis are clinically selected, 30 cases of test groups of 2 patients are randomly extracted to carry out treatment and observation on vaginal squamous epithelium repair aqua (called squamous aqua for short later), and 30 cases of control groups of 2 patients are carried out treatment and observation on estrogen (Hongli combined with estrogen cream, Xinjiang attitude source biological pharmacy Limited liability company).
The main symptoms of vaginal dryness are as follows: vaginal dryness, dyspareunia, with low vaginal health score (see table 1 below) and vaginal atrophy index (table 2). The patients in the test group applied the scaly aqua after cleaning private parts every night, the dosage of the scaly aqua is about 3ml each time, the treatment effect is evaluated according to clinical grading standard after the scaly aqua is continuously used for 14 days. The control group patients applied estrogen after cleaning private parts every night, the dosage of the estrogen is about 0.5g each time, the estrogen is used once a day, and the treatment effect is evaluated according to clinical grading standards after the estrogen is continuously used for 14 days. Evaluation criteria of treatment results of vaginal dryness: 1) the effect is shown: the main symptoms such as vaginal dryness and dyspareunia disappear, the vagina health score after the administration-before administration vagina health score is more than or equal to 2, and the vagina atrophy index after the administration-before administration vagina atrophy index is more than or equal to 2; 2) the method has the following advantages: relieving main symptoms such as vaginal dryness and dyspareunia, wherein the vaginal health score after administration-before administration vaginal health score is not less than 1, and the vaginal atrophy index after administration-before administration vaginal atrophy index is not less than 1; 3) and (4) invalidation: the main symptoms such as vaginal dryness and dyspareunia are not reduced, the vagina health score after the medicine is taken-before-the-vagina health score is less than 1, and the vagina atrophy index after the medicine is taken-before-the-vagina atrophy index is less than 1. The effective and effective cases are counted into clinical effective cases, and the clinical effective rate is calculated.
Table 1: vaginal health score
| Item | 1 minute (1) | 2 is divided into | 3 points of | 4 is divided into |
| Elasticity of | Is free of | Lack of | Medium and high grade | Women in the same sexual maturity stage |
| Degree of wetness | Non-wetting | Chinese character shao (a Chinese character of 'shao') | Medium and high grade | Women in the same sexual maturity stage |
| pH | 7 | 6 | 5 | 4 |
| Mucous membrane | Punctate hemorrhage | Palpation with blood | Thin sheet | Women in the same sexual maturity stage |
| Secretion material | Is free of | Lack of | Chinese character shao (a Chinese character of 'shao') | Normal amount |
Table 2: index of vaginal atrophy
The results of the test group and the control group on the treatment of vaginal dryness are shown in table 3:
table 3: treatment effect of vaginal dryness disease of patients in test group and control group
The results in table 3 show that the test group squamous water aqua has the significant efficiency of 43.3 percent on the vaginal dryness, the effective rate of 56.7 percent and the total effective rate of 100 percent; the obvious effective rate of the estrogen of the control group on the vaginal dryness is 50%, the effective rate is 43.3%, and the total effective rate is 93.3%. Therefore, the effect of the squamous water agent for treating vaginal dryness is not better than that of estrogen.
Secondly, the clinical symptoms of atrophic vaginitis are shown as follows: pruritus vulvae, burning pain of vulva and vagina, red swelling and congestion of vaginal wall, and leukorrhagia. The patients in the test group applied the scaly aqua after cleaning private parts every night, the dosage of the scaly aqua is about 3ml each time, the treatment effect is evaluated according to clinical grading standard after the scaly aqua is continuously used for 14 days. The control group patients applied estrogen after cleaning private parts every night, the dosage of the estrogen is about 0.5g each time, the estrogen is used once a day, and the treatment effect is evaluated according to clinical grading standards after the estrogen is continuously used for 14 days. The scoring criteria of clinical symptoms of atrophic vaginitis are shown in table 4, and the treatment effect is evaluated according to the score change percentage before and after the product is used: 1) the effect is shown: clinical symptoms disappear or are obviously improved, and the score change is more than or equal to 65 percent; 2) the method has the following advantages: the clinical symptoms are improved, and the score changes by 30-65%; 3) and (4) invalidation: no significant improvement in clinical symptoms occurred, with a score change of < 30%. The effective and effective cases are counted into clinical effective cases, and the clinical effective rate is calculated. The score change percentage calculation formula is as follows:
percent change score ═ 100% (pre-dose clinical score-post-dose clinical score)/pre-dose clinical score%
TABLE 4 atrophic vaginitis clinical symptom score criteria
The results of the treatment of atrophic vaginitis in the test and control groups are shown in table 5:
table 5: therapeutic effect of atrophic vaginitis of test group and control group
The results in table 5 show that the test group squamous water aqua has the significant efficiency of 40 percent, the effective rate of 53.3 percent and the total effective rate of 93.3 percent on atrophic vaginitis; the obvious effective rate of the estrogen of the control group on atrophic vaginitis is 50%, the effective rate is 40%, and the total effective rate is 90%. The squamous water aqua can achieve the treatment effect equivalent to that of estrogen on atrophic vaginitis.
The above description is only an embodiment of the present invention, and not intended to limit the scope of the present invention, and all modifications of equivalent structures and equivalent processes performed by the present invention in the specification and the content of the embodiment, or directly or indirectly applied to other related technical fields, are included in the scope of the present invention.
Claims (4)
1. The vaginal squamous epithelium repairing water aqua is characterized by comprising the following components in percentage by mass:
l-glutamine: 0.005% -1%;
0.001% -0.5% of epidermal cell growth factor;
transferrin: 0.001% -0.5%;
0.005% -1% of vitamin C;
hydrolyzing collagen: 0.1% -10%;
sodium hyaluronate: 0.1% -1.0%;
glycerol: 5% -10%;
lactic acid: 0.1% -1.0%;
sodium lactate: 0.2% -2.0%;
the balance being purified water.
2. The aqueous solution for repairing the vaginal squamous epithelium as claimed in claim 1, wherein the mass percentages of the components and the formula thereof are as follows:
l-glutamine 0.01%;
epidermal growth factor 0.02%;
transferrin is 0.02%;
vitamin C is 0.05%;
the hydrolyzed collagen is 2%;
0.2% of sodium hyaluronate;
5% of glycerin;
0.5 percent of lactic acid;
sodium lactate is 1 percent;
the purified water was 91.2%.
3. The method for preparing the aqueous agent for repairing the vaginal squamous epithelium, according to claim 1, is characterized in that: dissolving hydrolyzed collagen, sodium hyaluronate, glycerol, lactic acid and sodium lactate in purified water, heating to 80 deg.C, maintaining the temperature at 80 deg.C for 20 min, cooling, adding L-glutamine, epidermal growth factor, transferrin and vitamin C when the temperature of the system is reduced to below 40 deg.C, and stirring.
4. The preparation method of the aqueous agent for repairing vaginal squamous epithelium, according to claim 3, is characterized in that: the prepared aqueous solution is subpackaged in a trunk tube spray bottle, the front half section of the trunk tube wall of the spray bottle is provided with a plurality of uniformly arranged small holes, and when the spray bottle is used, the trunk tube of the spray bottle is deeply inserted into a vagina and is pressed to spray liquid to the vaginal wall.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911314731.2A CN110917132A (en) | 2019-12-19 | 2019-12-19 | Vaginal squamous epithelium repair aqua and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911314731.2A CN110917132A (en) | 2019-12-19 | 2019-12-19 | Vaginal squamous epithelium repair aqua and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110917132A true CN110917132A (en) | 2020-03-27 |
Family
ID=69863332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911314731.2A Pending CN110917132A (en) | 2019-12-19 | 2019-12-19 | Vaginal squamous epithelium repair aqua and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110917132A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114588252A (en) * | 2022-04-08 | 2022-06-07 | 暨南大学附属第一医院（广州华侨医院） | Composition for relieving vaginal atrophy and xerosis and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1324659A (en) * | 2000-05-23 | 2001-12-05 | 广州暨南大学医药生物技术研究开发中心 | Vagina spry containing biological active factor |
| CN105169374A (en) * | 2015-10-23 | 2015-12-23 | 东莞市达庆医疗器械有限公司 | Recombinant human collagen gel and preparation method thereof |
| CN106580871A (en) * | 2017-02-16 | 2017-04-26 | 杭州元研细胞生物科技有限公司 | Vaginal gel and preparation method thereof |
| CN108096138A (en) * | 2017-12-21 | 2018-06-01 | 广东科玮生物技术股份有限公司 | A kind of anti-aging skin repairs liquid and preparation method thereof |
| CN108992662A (en) * | 2018-08-23 | 2018-12-14 | 杭州元研细胞生物科技有限公司 | A kind of vagina of the factor containing mescenchymal stem cell is spraying and preparation method thereof |
| CN109589404A (en) * | 2018-11-27 | 2019-04-09 | 杭州元研细胞生物科技有限公司 | One kind is for anti-ageing reparation product of female reproductive system and preparation method thereof |
| CN109646671A (en) * | 2018-12-26 | 2019-04-19 | 陕西三八妇乐科技股份有限公司 | A kind of growth-factor preparation and its preparation method and application |
-
2019
- 2019-12-19 CN CN201911314731.2A patent/CN110917132A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1324659A (en) * | 2000-05-23 | 2001-12-05 | 广州暨南大学医药生物技术研究开发中心 | Vagina spry containing biological active factor |
| CN105169374A (en) * | 2015-10-23 | 2015-12-23 | 东莞市达庆医疗器械有限公司 | Recombinant human collagen gel and preparation method thereof |
| CN106580871A (en) * | 2017-02-16 | 2017-04-26 | 杭州元研细胞生物科技有限公司 | Vaginal gel and preparation method thereof |
| CN108096138A (en) * | 2017-12-21 | 2018-06-01 | 广东科玮生物技术股份有限公司 | A kind of anti-aging skin repairs liquid and preparation method thereof |
| CN108992662A (en) * | 2018-08-23 | 2018-12-14 | 杭州元研细胞生物科技有限公司 | A kind of vagina of the factor containing mescenchymal stem cell is spraying and preparation method thereof |
| CN109589404A (en) * | 2018-11-27 | 2019-04-09 | 杭州元研细胞生物科技有限公司 | One kind is for anti-ageing reparation product of female reproductive system and preparation method thereof |
| CN109646671A (en) * | 2018-12-26 | 2019-04-19 | 陕西三八妇乐科技股份有限公司 | A kind of growth-factor preparation and its preparation method and application |
Non-Patent Citations (1)
| Title |
|---|
| 汪多仁编著: "《绿色医药化学品》", 31 July 2008, 科技文献出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114588252A (en) * | 2022-04-08 | 2022-06-07 | 暨南大学附属第一医院（广州华侨医院） | Composition for relieving vaginal atrophy and xerosis and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104587518A (en) | Hyaluronic acid dressing and preparation method thereof | |
| CN108348636B (en) | Mussel mucin product and application thereof in inhibiting mucosal inflammation | |
| CN111632075B (en) | Exosome preparation for promoting skin wound healing and preparation method thereof | |
| CN101780031B (en) | Induced gel used for repairing skin wound surfaces or cervical mucosa | |
| CN103182070B (en) | External composition, and preparation and application thereof | |
| CN108992662A (en) | A kind of vagina of the factor containing mescenchymal stem cell is spraying and preparation method thereof | |
| CN108452293A (en) | A kind of gynaecology's gel and preparation method thereof | |
| CN105250696A (en) | Traditional Chinese medicine gel capable of promoting skin wound to heal and preparation method of traditional Chinese medicine gel | |
| CN110917132A (en) | Vaginal squamous epithelium repair aqua and preparation method thereof | |
| CN113730433B (en) | Gynecological gel for treating colpitis and preparation method and application thereof | |
| CN104147108B (en) | Bacteriostatic gel containing brown alga oligose | |
| CN100502953C (en) | Wound surface active repairing material | |
| CN109010124A (en) | A kind of ocean essence gynaecology bacteriostatic gel and preparation method thereof | |
| CN106581741A (en) | Reconstructed human source collagen paste and preparation method thereof | |
| CN111214694A (en) | Dressing with functions of stopping bleeding and accelerating wound healing and preparation method thereof | |
| CN108938703A (en) | The gynecological gel of quick antibacterial | |
| CN109646671A (en) | A kind of growth-factor preparation and its preparation method and application | |
| CN107596370A (en) | A kind of drug compound preparation and purposes for treating cervical erosion | |
| CN112121146B (en) | A topical gel for treating skin wound, and its preparation method | |
| CN103520707B (en) | A kind of beneficial bacterium controls the compositions that bacterium prevention and therapy gynaecologic reproductive system infects | |
| AU2021104085A4 (en) | Hpv-resistant lactic acid bacteria gynecological preparation and application thereof | |
| CN117180492B (en) | Gel dressing composition containing silk fibroin, preparation method and application | |
| CN111920825B (en) | anti-HPV composition for female genital tract and application thereof | |
| CN103816110A (en) | Preparation method of drug transdermal absorbent promoting fracture healing | |
| CN110433236B (en) | Traditional Chinese medicine composition for promoting wound healing and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200327 |
|
| RJ01 | Rejection of invention patent application after publication |